Development of a Ferroptosis-Related lncRNA Signature to Predict the Prognosis and Immune Landscape of Bladder Cancer

Figure 3

Validation of the lncRNA signature. (a) AUC of time-dependent ROC curves. (b) Comparison of 5-year ROC curves with other clinicopathological features. (c) Kaplan–Meier survival plot for OS in cases in the high- and low-risk groups (). (d and e) Scatter diagrams showing the risk scores (d) and survival status (e) of BCa cases. (f) Results of enrichment analysis using LncSEA. (g–i) Prognostic values of ImmuneScore (g, ), StromalScore (h, ), and ESTIMATEScore (i, ). The optimal cutoffs were determined using X-tile software. (j–k) The risk score was superior to ImmuneScore, StromalScore, and ESTIMATEScore in predicting OS in univariate (j) and multivariate Cox analyses (k). AUC: area under curve; ROC: receiver operating characteristic; OS: overall survival; BCa: bladder cancer.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)